Abbvie raises sales outlook of two immunology drugs to more than $17.5 billion in 2025
(Reuters) -AbbVie Inc on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira. The company’s previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion. …
Abbvie raises sales outlook of two immunology drugs to more than $17.5 billion in 2025 Read More »